Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Feb;176(2):301-310.
doi: 10.1002/ajmg.a.38551. Epub 2017 Dec 6.

Intrafamilial variability in the clinical manifestations of mucopolysaccharidosis type II: Data from the Hunter Outcome Survey (HOS)

Can Ficicioglu  1 , Roberto Giugliani  2 , Paul Harmatz  3 , Nancy J Mendelsohn  4   5 , Virginie Jego  6 , Rossella Parini  7
Affiliations

Intrafamilial variability in the clinical manifestations of mucopolysaccharidosis type II: Data from the Hunter Outcome Survey (HOS)

Can Ficicioglu et al. Am J Med Genet A. 2018 Feb.

Abstract

Several cases of phenotypic variability among family members with mucopolysaccharidosis type II (MPS II) have been reported, but the data are limited. Data from patients enrolled in the Hunter Outcome Survey (HOS) were used to investigate intrafamilial variability in male siblings with MPS II. As of July 2015, data were available for 78 patients aged ≥5 years at last visit who had at least one affected sibling (39 sibling pairs). These patients were followed prospectively (i.e., they were alive at enrollment in HOS). The median age at the onset of signs and symptoms was the same for the elder and younger brothers (2.0 years); however, the younger brothers were typically diagnosed at a younger age than the elder brothers (median age, 2.5 and 5.1 years, respectively). Of the 39 pairs, eight pairs were classified as being discordant (the status of four or more signs and symptoms differed between the siblings); 21 pairs had one, two, or three signs and symptoms that differed between the siblings, and 10 pairs had none. Regression status of the majority of the developmental milestones studied was generally concordant among siblings. Functional classification, a measure of central nervous system involvement, was the same in 24/28 pairs, although four pairs were considered discordant as functional classification differed between the siblings. Overall, this analysis revealed similarity in the clinical manifestations of MPS II among siblings. This information should help to improve our understanding of the clinical presentation of the disease, including phenotype prediction in affected family members.

Keywords: Hunter syndrome; clinical heterogeneity; idursulfase; lysosomal storage disease; siblings.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Height and duration of treatment in siblings for whom height data were available at the given age time point for both siblings. Sibling 1 was the elder sibling. S1, sibling 1; S2, sibling 2
See this image and copyright information in PMC

References

    1. Al Sawaf, S. , Mayatepek, E. , & Hoffmann, B. (2008). Neurological findings in Hunter disease: Pathology and possible therapeutic effects reviewed. Journal of Inherited Metabolic Diseases, 31(4), 473 –480. - PubMed
    1. Alcalde‐Martin, C. , Muro‐Tudelilla, J. M. , Cancho‐Candela, R. , Gutierrez‐Solana, L. G. , Pintos‐Morell, G. , Marti‐Herrero, M. , … Galan‐Gomez, E. (2010). First experience of enzyme replacement therapy with idursulfase in Spanish patients with Hunter syndrome under 5 years of age: Case observations from the Hunter Outcome Survey (HOS). European Journal of Medical Genetics, 53(6), 371 –377. - PubMed
    1. American Psychiatric Association. (2000). Diagnostic and statistical manual of mental disorders: DSM‐IV‐TR. 4th ed. (pp. 3421–3452). Washington, DC: American Psychiatric Association. (8, Trans.).
    1. Baehner, F. , Schmiedeskamp, C. , Krummenauer, F. , Miebach, E. , Bajbouj, M. , Whybra, C. , … Beck, M. (2005). Cumulative incidence rates of the mucopolysaccharidoses in Germany. Journal of Inherited Metabolic Disorder, 28(6), 1011–1017. - PubMed
    1. Burton, B. K. , Guffon, N. , Roberts, J. , van der Ploeg, A. T. , & Jones, S. A. (2010). Home treatment with intravenous enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II? data from the Hunter Outcome Survey. Molecular Genettics and Metabolism, 101(2‐3), 123 –129. - PubMed

Publication types